

**REVOCATION OF POWER OF  
 ATTORNEY WITH  
 NEW POWER OF ATTORNEY  
 AND  
 CHANGE OF CORRESPONDENCE ADDRESS**

Application Number	10/098,695
Filing Date	March 15, 2002
First Named Inventor	Sidney D. Fleischman
Art Unit	NA
Examiner Name	NA
Attorney Docket Number	1001.2632103

**I hereby revoke all previous powers of attorney given in the above-identified application.**

☐ A Power of Attorney is submitted herewith.

**OR**

☒ I hereby appoint the practitioners associated with the Customer Number:

11050

☒ Please change the correspondence address for the above-identified application to:

☒ The address associated with  
 Customer Number:

11050

**OR**

☐ Firm or  
 Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
 Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)

**SIGNATURE of Applicant or Assignee of Record**

Signature /todd messal/

Name Todd Messal, Patent Attorney for Boston Scientific Scimed, Inc.

Date March 11, 2011

Telephone

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☐ \*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**LIMITED AUTHORIZATION TO ACT ON BEHALF OF ASSIGNEE  
REGARDING CERTAIN PATENT MATTERS  
EFFECTIVE THROUGH: December 31, 2011**

I, Timothy A. Pratt, as Executive Vice President, Chief Administrative Officer, General Counsel and Secretary of Boston Scientific Corporation, the controlling corporation of:

A-Med Systems, Inc.; Action Medical, Inc.; Adam Acquisition 2001 Inc.; Advanced Bionics Corporation; Advanced Stent Technologies, Inc.; Advanced Stent Technologies, LLC; AFX, Inc.; AMS Medivent S.A.; Angiomedics Incorporated; Ashtamix Inc.; BEI Medical Systems; BEI Medical Systems Company, Inc.; BEI Medical Systems International, Inc.; BEI Medical Systems Operating Company (formerly known as Xylog Corporation); Boston Scientific BV; Boston Scientific Corporation Northwest Technology Center, Inc.; Boston Scientific Cupertino Corp.; Boston Scientific Glens Falls Corp.; Boston Scientific Ireland Limited; Boston Scientific Japan KK; Boston Scientific Limited; Boston Scientific Miami Corporation; Boston Scientific Mountain View Corporation; Boston Scientific Neuromodulation Corporation; Boston Scientific Santa Rosa Corp.; Boston Scientific Scimed, Inc. (formerly known as Schneider (USA), Inc.); Boston Scientific Scimed, Inc. (formerly known as Scimed Life Systems, Inc.); Boston Scientific Technology Inc.; Boston Scientific Wayne Corporation; Broadway Acquisition Corporation; BSC Technology, Inc.; Cardiac Pacemakers, Inc.; Cardiac Pathways Corporation; CardioGene Therapeutics, Inc.; Cardiothoracic Systems, Inc.; Cardiovascular Imaging Systems, Inc.; Cardiovascular Innovations Canada, Inc.; Catheter Innovations Corp.; Celsion Corporation; Charger Acquisition Corp.; Claude Acquisition Corporation; Corvita Canada, Inc.; Corvita Corporation; Corvita Europe S.A.; CRV Acquisition Corp.; CryoCor, Inc.; CryoVascular Systems, Inc.; Embolix Protection, Inc.; Embro Vascular, LLC; Enable Medical Corporation; EndoTex Interventional Systems, Inc.; Endovascular Technologies, Inc. (EVT); Enteric Medical Technologies, Inc.; EP Technologies, Inc.; Fidus Medical Technology Corporation; Guidant Corporation; Guidant Foundation; Guidant Holdings, Inc.; Guidant Intercontinental Corporation; Guidant Investment Corporation; Guidant Puerto Rico Sales Corporation; Guidant Sales Corporation; Heart Technology Inc.; Heart Technology Manufacturing, Inc.; ID Acquisition Corp.; Incept LLC; Inflow Dynamics Inc.; Intermedics, Inc.; Interventional Technologies, Inc.; Interventional Therapeutics Corporation; Interventional Therapeutics Int'l; KPS Acquisition Corporation; Labcoat Limited; Laboratoires Corvita S.A.R.L.; Mansfield Scientific, Inc.; Meadox Medicals, Inc.; Meadox Technologies, Inc.; Medi-Tech Incorporation; Merger Sub, Inc.; Microvasive, Inc.; MW Medical, Inc.; NAMIC Caribe, Inc.; NAMIC Bireann Limited; NAMIC International, Inc.; NAMIC U.S.A. Corporation; Nemo I Acquisition, Inc.; Neuro Interventions, Inc.; New Heart Technology, Inc.; Nilo Holding, S.A.; North American Instrument Corporation; Novoste Puerto Rico Inc.; Odyssey Technologies, Inc.; Origin Medsystems, Inc.; Precision Vascular Systems, Inc.; Prohold Medical Corporation; Prohold Technologies, Inc.; Provasis Therapeutics, Inc.; Quantum Medical Corporation; Radio Therapeutics Corporation; Remon Medical Technologies, Ltd.; Rubicon Medical Corporation; Rubicon Medical, Inc.; Schneider (Europe) GmbH; Schneider (USA) Inc.; Schneider Belgium NV; Schneider Holland BV; Schneider Ireland BV; Schneider Puerto Rico (formerly known as NAMIC Caribe, Inc.); Schneider/NAMIC; Schneider-Shiley (USA) Inc.; Scimed Life Systems, Inc.; Scimed Technology, Inc.; Scimed, Inc.; Smart Therapeutics, Inc.; Sub-Q, Inc.; Surgimed, Inc.; Symbiosis Corporation; Target Therapeutics, Inc.; Trivascular 2, Inc.; TriVascular, Inc.; Van-Tec, Inc.; and Vesia Medical Inc.;

hereby authorize the following registered patent attorneys/agents (1) to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent entities, (2) to execute power of attorney documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, to appoint and/or establish any attorneys, agents, and/or law firms to act on behalf of any of the corporations identified above, including Boston Scientific Corporation, in any foreign or international patent applications filed with any foreign and/or international patent offices, and (3) to execute assignment and ownership documents on behalf of any of the corporations identified above, including Boston Scientific Corporation, with regard to any matters before the United States Patent and Trademark Office, any foreign patent offices, and any international patent offices:

Victoria Aguilera Poissant .....Reg. No. 56,871  
Alana Bergman .....Reg. No. 47,420  
James R. Chiappetta .....Reg. No. 39,634  
Sara J. Citrowske .....Reg. No. 55,076  
Jeffrey P. Cook .....Reg. No. 48,649  
Luke R. Dohmen .....Reg. No. 36,783  
Peter J. Gafner .....Reg. No. 36,517  
Lori J. Heinrichs .....Reg. No. 43,667  
Albert K. Kawa .....Reg. No. 40,672

Phillip H. Lee .....Reg. No. 50,645  
Kurt W. Lockwood .....Reg. No. 40,704  
Jeffrey Z. Mann .....Reg. No. 51,994  
Steven A. McAuley .....Reg. No. 46,084  
Todd P. Messal .....Reg. No. 42,883  
Tyler L. Nasiedlak .....Reg. No. 40,099  
Peter Nigrelli .....Reg. No. 66,461  
William J. Shaw .....Reg. No. 43,111  
Kimberly S. Zillig .....Reg. No. 46,346

Timothy A. Pratt, Executive Vice President, Chief Administrative Officer, General Counsel and Secretary

Date

COMMONWEALTH OF MASSACHUSETTS

)  
) ss.  
)

COUNTY OF MIDDLESEX

On this 13th day of January, 2011, before me personally appeared Timothy A. Pratt to me known and known to me to be the person described in and who executed the foregoing instrument, and he duly acknowledged to me that he executed the same for the uses and purposes set forth herein.

Notary Public



**NONIE E. HURD**  
Notary Public  
Commonwealth of Massachusetts  
My Commission Expires  
September 2, 2018